Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.44 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25566632 | 0.72 | ADORA3 (0.53) | ADORA3ADORA1HSP90B1TMIGD3ADORA2A | |
| SCHEMBL25566745 | 0.72 | ADORA3 (0.62) | ADORA3ADORA1TMIGD3ADORA2A | |
| SCHEMBL19423461 | 0.69 | ADORA3 (0.77) | ADORA3ADORA1HSP90B1ADORA2AHSP90AA1 | |
| SCHEMBL15462103 | 0.69 | ADORA3 (0.77) | ADORA3ADORA1HSP90B1ADORA2AHSP90AA1 | |
| SCHEMBL19813951 | 0.65 | CHKA (0.51) | — | |
| SCHEMBL19813952 | 0.65 | CHKA (0.51) | — | |
| SCHEMBL5816714 | 0.65 | ADORA3 (0.82) | ADORA3ADORA1HSP90B1TMIGD3ADORA2A | |
| SCHEMBL5816711 | 0.65 | ADORA3 (0.82) | ADORA3ADORA1HSP90B1TMIGD3ADORA2A | |
| SCHEMBL29353246 | 0.64 | CHKA (0.49) | ADORA3ADORA1ADORA2A | |
| SCHEMBL3427635 | 0.64 | ADORA3 (0.74) | ADORA3ADORA2ADNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091791-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |